Compare Crispr Therapeutics AG (CRSP) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs PAGSEG Inc — how do they compare? Crispr Therapeutics AG trades at $54.07 (market cap $5.23B), while PAGSEG Inc trades at $8.67 (market cap $2.48B). The key difference: Crispr Therapeutics AG is far larger — about 2.1× PAGSEG Inc's market cap, and PAGSEG Inc pays a 11.7% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | PAGS | |
|---|---|---|
Market Cap | $5.23B | $2.48B |
Sector | Health | Technology |
52-Week High | $76.78 | $12.00 |
52-Week Low | $44.34 | $8.38 |
Enterprise Value | $3.65B | $10.22B |
Dividend Yield | — | 11.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
PAGS trades at $8.70, down 4.19% over 24 hours, reflecting recent bearish technical signals. The stock shows strong fundamentals with a P/E of 6.17 and net income margin of 10.4%, while Q2 2026 earnings beat expectations. Recent news highlights robust Q2 2026 results, including R$576 million recurring net income and growth in deposits and loans, per PRNewsWire on August 12, 2026.
The outlook is mixed; low valuations and analyst consensus of $11.45 price target suggest upside, but technical bearishness and CEO share sales pose risks. Investors may find value in earnings growth potential, though market volatility and competitive pressures require caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
